165 related articles for article (PubMed ID: 21254154)
1. Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis.
Sugimoto M; Oka M; Tsunemori H; Yamashita M; Kakehi Y
Prostate; 2011 Mar; 71(4):438-44. PubMed ID: 21254154
[TBL] [Abstract][Full Text] [Related]
2. Effect of the phytotherapeutic agent Eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate.
Oka M; Ueda M; Oyama T; Kyotani J; Tanaka M
Prostate; 2009 Sep; 69(13):1404-10. PubMed ID: 19489033
[TBL] [Abstract][Full Text] [Related]
3. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate.
Shibuya S; Xia Z; Sugimoto M; Ueda N; Haba R; Kakehi Y
Urology; 2014 Mar; 83(3):528-34. PubMed ID: 24581515
[TBL] [Abstract][Full Text] [Related]
4. Effect of the phytotherapeutic agent Eviprostat on inflammatory changes and cytokine production in a rat model of nonbacterial prostatitis.
Tsunemori H; Sugimoto M; Xia Z; Taoka R; Oka M; Kakehi Y
Urology; 2011 Jun; 77(6):1507.e15-20. PubMed ID: 21624608
[TBL] [Abstract][Full Text] [Related]
5. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis.
Tagaya M; Oka M; Ueda M; Takagaki K; Tanaka M; Ohgi T; Yano J
Cytokine; 2009 Sep; 47(3):185-93. PubMed ID: 19616448
[TBL] [Abstract][Full Text] [Related]
6. Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia.
Matsumoto S; Hanai T; Matsui T; Oka M; Tanaka M; Uemura H
Phytother Res; 2010 Feb; 24(2):301-3. PubMed ID: 19585469
[TBL] [Abstract][Full Text] [Related]
7. Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction.
Oka M; Fukui T; Ueda M; Tagaya M; Oyama T; Tanaka M
J Urol; 2009 Jul; 182(1):382-90. PubMed ID: 19447421
[TBL] [Abstract][Full Text] [Related]
8. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
[TBL] [Abstract][Full Text] [Related]
9. Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying.
Kawai Y; Oka M; Kyotani J; Oyama T; Matsumoto S; Kakizaki H
Neurourol Urodyn; 2013 Sep; 32(7):1031-7. PubMed ID: 23143863
[TBL] [Abstract][Full Text] [Related]
10. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
[TBL] [Abstract][Full Text] [Related]
11. Effect of eviprostat on bladder overactivity in an experimental cystitis rat model.
Kobayashi M; Nomura M; Nishii H; Matsumoto S; Fujimoto N; Matsumoto T
Int J Urol; 2008 Apr; 15(4):356-60. PubMed ID: 18380828
[TBL] [Abstract][Full Text] [Related]
12. Improvement by phytotherapeutic agent of detrusor overactivity, down-regulation of pharmacological receptors and urinary cytokines in rats with cyclophosphamide induced cystitis.
Nasrin S; Masuda E; Kugaya H; Ito Y; Yamada S
J Urol; 2013 Mar; 189(3):1123-9. PubMed ID: 23000860
[TBL] [Abstract][Full Text] [Related]
13. Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia.
Matsui T; Oka M; Fukui T; Tanaka M; Oyama T; Sagawa K; Nomiya M; Yamaguchi O
Int J Urol; 2012 Jul; 19(7):669-75. PubMed ID: 22458726
[TBL] [Abstract][Full Text] [Related]
14. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Kaplan SA
J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
[No Abstract] [Full Text] [Related]
15. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
Matsuura T; Wakabayashi A; Kaneko S; Kurita T
Hinyokika Kiyo; 1986 Jun; 32(6):903-6. PubMed ID: 2429533
[TBL] [Abstract][Full Text] [Related]
16. Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.
Ishigooka M; Hashimoto T; Hayami S; Tomaru M; Nakada T; Mitobe K
Int Urol Nephrol; 1995; 27(1):61-6. PubMed ID: 7542229
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms by which a phytotherapeutic drug influences bladder activity in rats.
Sugaya K; Nishijima S; Tasaki S; Kadekawa K; Miyazato M; Ogawa Y
J Urol; 2008 Feb; 179(2):770-4. PubMed ID: 18082195
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment to suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia.
Yamada S
Int J Urol; 2012 Jul; 19(7):675; author reply 675. PubMed ID: 22725604
[No Abstract] [Full Text] [Related]
20. [Effect of prostamol-Uno on oxidative and local immune status in patients with benign prostatic hyperplasia and chronic prostatitis].
Seregin SP; Bratchikov OI; Konoplia AI; Shestakov SG; Dolzhenkov SD; Novikov AV; Shatokhin MN; Kotov AV
Urologiia; 2002; (4):14-6. PubMed ID: 12357892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
